AU2019310919B2 - Compounds for use in treating kidney disorders - Google Patents

Compounds for use in treating kidney disorders Download PDF

Info

Publication number
AU2019310919B2
AU2019310919B2 AU2019310919A AU2019310919A AU2019310919B2 AU 2019310919 B2 AU2019310919 B2 AU 2019310919B2 AU 2019310919 A AU2019310919 A AU 2019310919A AU 2019310919 A AU2019310919 A AU 2019310919A AU 2019310919 B2 AU2019310919 B2 AU 2019310919B2
Authority
AU
Australia
Prior art keywords
cpd
vehicle
adr
day
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019310919A
Other languages
English (en)
Other versions
AU2019310919A1 (en
Inventor
Alessia Fornoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2019310919A1 publication Critical patent/AU2019310919A1/en
Application granted granted Critical
Publication of AU2019310919B2 publication Critical patent/AU2019310919B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019310919A 2018-07-26 2019-07-26 Compounds for use in treating kidney disorders Active AU2019310919B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18185871.3 2018-07-26
EP18185871 2018-07-26
PCT/EP2019/070251 WO2020021097A1 (en) 2018-07-26 2019-07-26 Compounds for use in treating kidney disorders

Publications (2)

Publication Number Publication Date
AU2019310919A1 AU2019310919A1 (en) 2021-01-07
AU2019310919B2 true AU2019310919B2 (en) 2025-04-03

Family

ID=63077813

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019310919A Active AU2019310919B2 (en) 2018-07-26 2019-07-26 Compounds for use in treating kidney disorders

Country Status (13)

Country Link
US (3) US20200085810A1 (enExample)
EP (2) EP4537901A3 (enExample)
JP (2) JP7478133B2 (enExample)
KR (1) KR102860768B1 (enExample)
CN (2) CN112469442B (enExample)
AU (1) AU2019310919B2 (enExample)
CA (1) CA3104793A1 (enExample)
ES (1) ES3005632T3 (enExample)
IL (1) IL280368B2 (enExample)
MX (1) MX2021000976A (enExample)
PL (1) PL3826679T3 (enExample)
TW (1) TWI891608B (enExample)
WO (1) WO2020021097A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
WO2022006277A1 (en) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Methods for treatment of fibrotic kidney diseases
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011053948A1 (en) * 2009-11-02 2011-05-05 Sanofi-Aventis Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals
WO2012101197A1 (en) * 2011-01-26 2012-08-02 Sanofi Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
US20120316147A1 (en) * 2011-06-10 2012-12-13 Caterina Bissantz Novel pyridine derivatives
WO2015004089A1 (en) * 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Losmapimod for use in treating glomerular disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270846B (it) 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
MXPA06010815A (es) 2004-03-26 2006-12-15 Hoffmann La Roche Tetrahidrocarbazoles y derivados de los mismos.
EP1756096B1 (en) 2004-05-03 2009-08-12 F.Hoffmann-La Roche Ag Indolyl derivatives as liver-x-receptor modulators
UA107088C2 (xx) * 2009-09-11 2014-11-25 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
BR112014005634A2 (pt) 2011-09-12 2017-03-28 Hoffmann La Roche hidrazidas de 3-piridina ácido carboxílico como agentes de aumento de colesterol hdl
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011053948A1 (en) * 2009-11-02 2011-05-05 Sanofi-Aventis Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals
WO2012101197A1 (en) * 2011-01-26 2012-08-02 Sanofi Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
US20120316147A1 (en) * 2011-06-10 2012-12-13 Caterina Bissantz Novel pyridine derivatives
WO2015004089A1 (en) * 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Losmapimod for use in treating glomerular disease

Also Published As

Publication number Publication date
PL3826679T3 (pl) 2025-03-10
JP7478133B2 (ja) 2024-05-02
KR20210038884A (ko) 2021-04-08
IL280368B1 (en) 2023-10-01
CA3104793A1 (en) 2020-01-30
JP2024096989A (ja) 2024-07-17
EP3826679B1 (en) 2024-11-27
EP4537901A2 (en) 2025-04-16
US20240325372A1 (en) 2024-10-03
TW202019486A (zh) 2020-06-01
JP2021531308A (ja) 2021-11-18
KR102860768B1 (ko) 2025-09-17
EP4537901A3 (en) 2025-05-21
AU2019310919A1 (en) 2021-01-07
US20200085810A1 (en) 2020-03-19
TWI891608B (zh) 2025-08-01
WO2020021097A1 (en) 2020-01-30
IL280368A (en) 2021-03-25
ES3005632T3 (en) 2025-03-14
US20210275514A1 (en) 2021-09-09
IL280368B2 (en) 2024-02-01
EP3826679C0 (en) 2024-11-27
EP3826679A1 (en) 2021-06-02
CN112469442A (zh) 2021-03-09
CN117736141A (zh) 2024-03-22
CN112469442B (zh) 2024-04-09
MX2021000976A (es) 2021-03-31

Similar Documents

Publication Publication Date Title
US20240325372A1 (en) Compounds for use in treating kidney disorders
RS54492B1 (sr) Kinazni inhibitor koji reguliše signalni put apoptoze
JP2023526055A (ja) 前立腺癌を治療する方法
US20110288114A1 (en) Compositions for the treatment of fibrotic diseases or conditions
CN113924295A (zh) 激酶抑制剂
BRPI0618524A2 (pt) uso de diaril ureias para o tratamento de hipertensão pulmonar, bem como combinação e composição compreendendo as referidas diaril ureias e uso da combinação
CN110267660A (zh) 含布罗莫结构域蛋白4(brd4)的抑制剂
WO2012036193A1 (ja) P2x7受容体阻害物質を有効成分とする脂肪性肝疾患治療剤
US9403755B2 (en) Isometheptene isomer
HK40040900A (en) Compounds for use in treating kidney disorders
HK40102350A (zh) 用於治疗肾脏疾患的化合物
CA3224123A1 (en) Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2)
HK40040900B (zh) 用於治疗肾脏疾患的化合物
WO2021205341A1 (en) 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases
WO2024098005A1 (en) Composition comprising glp-1 receptor agonist and acat inhibitor
EA047522B1 (ru) Комбинация антагониста азетидиновых рецепторов lpa1 с пирфенидоном и/или нинтеданибом для применения для лечения фиброзных заболеваний
WO2006060190A2 (en) Imidazole derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)